Savara (SVRA) Stock: Buy, Sell, or Hold?
SVRA - Savara Inc.
$4.22
-0.32 (-7.05%)
▼
5d:
-5.17%
30d:
-16.77%
90d:
-22.28%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When SVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SVRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SVRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SVRA is currently trading at $4.22, which is considered oversold relative to its 30-day fair value range of $4.64 to $5.23.
Technical Outlook: Technically, SVRA is in a strong uptrend. The price is currently testing key support at $4.13. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: SVRA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.06 (+162.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SVRA is in a strong uptrend. The price is currently testing key support at $4.13. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: SVRA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.06 (+162.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.64 -
$5.23
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.0%)
- BULLISH: Trading 162.0% below Wall St target ($11.06)
- CAUTION: 5-day price weakness (-5.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$4.64 -
$5.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.13
Resistance Level
$5.02
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.50
Wall Street Target
$11.06
(+162.0%)
Share & Embed Analysis
Last updated: October 23, 2026 10:50 PM ET
Data refreshes hourly during market hours. Next update: 11:50 PM
Data refreshes hourly during market hours. Next update: 11:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 66 BUY |